| HOME >> BIOLOGY >> TECHNOLOGY |
Mozobil(TM) (plerixafor) for stem-cell transplantation
-- Genzyme plans to file mid year for U.S. and European approval for
Mozobil's use in treating patients with multiple myeloma and patients
with lymphoma. The company expects to launch the product in the United
States early next year upon approval and to rapidly expand the
product's availability around the world. The company anticipates peak
annual sales of the product in the transplant setting of $400 million.
Mozobil is an innovative product intended to enhance the mobilization
of stem cells for transplantation in patients with lymphoma and
multiple myeloma. In two pivotal clinical studies, Mozobil showed the
ability to quickly and predictably prepare cancer patients for a
transplant to treat their disease. Genzyme is also exploring
additional indications for Mozobil, including its potential use in
chemosensitization procedures.
Clolar for adult AML
-- Clolar is approved in the United States and Europe for the treatment of
acute lymphoblastic leukemia in relapsed and refractory pediatric
patients. Genzyme is developing the product for use globally as a
first-line therapy for the treatment of adult acute myeloid leukemia
(AML) and myelodysplastic syndromes, significantly larger indications
that the company estimates will drive peak annual sales of the product
to approximately $600 million. The company intends to submit a
supplemental new drug application in the United States later this year
to include an adult AML indication. This application will be based on
results from the CLASSIC II clinical trial involving older adult AML
<| SOURCE Genzyme Corp. Copyright©2008 PR Newswire. All rights reserved |